PortalPublikationenFemale gender is associated with higher risk of disease recu...

Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.

Standard

Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. / Kluth, Luis A; Fajkovic, Harun; Xylinas, Evanguelos; Crivelli, Joseph J; Passoni, Niccolo; Rouprêt, Morgan; Becker, Andreas; Comploj, Evi; Pycha, Armin; Holmang, Sten; Gupta, Amit; Lotan, Yair; Karakiewicz, Pierre I; Gontero, Paolo; Chun, Felix K-H; Fisch, Margit; Scherr, Douglas S; Shariat, Shahrokh F.

in: WORLD J UROL, Jahrgang 31, Nr. 5, 2013, S. 1029-36.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kluth, LA, Fajkovic, H, Xylinas, E, Crivelli, JJ, Passoni, N, Rouprêt, M, Becker, A, Comploj, E, Pycha, A, Holmang, S, Gupta, A, Lotan, Y, Karakiewicz, PI, Gontero, P, Chun, FK-H, Fisch, M, Scherr, DS & Shariat, SF 2013, 'Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.', WORLD J UROL, Jg. 31, Nr. 5, S. 1029-36. https://doi.org/10.1007/s00345-012-0996-9

APA

Kluth, L. A., Fajkovic, H., Xylinas, E., Crivelli, J. J., Passoni, N., Rouprêt, M., Becker, A., Comploj, E., Pycha, A., Holmang, S., Gupta, A., Lotan, Y., Karakiewicz, P. I., Gontero, P., Chun, F. K-H., Fisch, M., Scherr, D. S., & Shariat, S. F. (2013). Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. WORLD J UROL, 31(5), 1029-36. https://doi.org/10.1007/s00345-012-0996-9

Vancouver

Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. WORLD J UROL. 2013;31(5):1029-36. https://doi.org/10.1007/s00345-012-0996-9

Bibtex

@article{06b1431e61644c319b6d287943e600d7,
title = "Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.",
abstract = "PURPOSE: An increasing body of evidence suggests gender differences in the presentation and prognosis of bladder cancer. We aimed to assess the impact of gender on outcomes in patients with primary T1 high-grade (HG) urothelial carcinoma of the bladder (UCB).METHODS: We retrospectively analysed the data from 916 patients with primary T1HG UCB from 7 tertiary care centres. Patients were treated with transurethral resection of the bladder with or without intravesical instillation therapy (IVT). Univariable and multivariable Cox regression analyses assessed the effect of gender on outcomes.RESULTS: Within a median follow-up of 42.8 months, 365 (39.8 %) patients experienced disease recurrence, 104 (11.4 %) progression, 59 (6.4 %) cancer-specific mortality and 190 (20.7 %) mortality of any cause. Overall, 634 (69.2 %) patients received IVT of which 234 (25.5 %) received BCG therapy. Female gender (n = 190, 20.7 %) was associated with higher risk of disease recurrence (HR:1.359;1.071-1.724, p = 0.012) in all patients and in a subgroup of patients treated with BCG therapy (HR:1.717;1.101-2.677, p = 0.017). There was no difference between genders with regard to disease progression, cancer-specific mortality and any-cause mortality. In multivariable analyses that adjusted for the effects of concomitant carcinoma in situ (CIS), tumour size, number of tumours, and IVT, gender remained an independent predictor for disease recurrence (p = 0.026) when analysed in all patients, but not in the subgroup of BCG treated patients (p = 0.093).CONCLUSIONS: In patients with T1HG UCB, female gender is associated with higher risk of disease recurrence, but not with disease progression. This gender disparity may be due to differences in care and/or biology of UCB.",
keywords = "Administration, Intravesical, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Transitional Cell, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Regression Analysis, Retrospective Studies, Risk Factors, Sex Factors, Urinary Bladder Neoplasms",
author = "Kluth, {Luis A} and Harun Fajkovic and Evanguelos Xylinas and Crivelli, {Joseph J} and Niccolo Passoni and Morgan Roupr{\^e}t and Andreas Becker and Evi Comploj and Armin Pycha and Sten Holmang and Amit Gupta and Yair Lotan and Karakiewicz, {Pierre I} and Paolo Gontero and Chun, {Felix K-H} and Margit Fisch and Scherr, {Douglas S} and Shariat, {Shahrokh F}",
year = "2013",
doi = "10.1007/s00345-012-0996-9",
language = "English",
volume = "31",
pages = "1029--36",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.

AU - Kluth, Luis A

AU - Fajkovic, Harun

AU - Xylinas, Evanguelos

AU - Crivelli, Joseph J

AU - Passoni, Niccolo

AU - Rouprêt, Morgan

AU - Becker, Andreas

AU - Comploj, Evi

AU - Pycha, Armin

AU - Holmang, Sten

AU - Gupta, Amit

AU - Lotan, Yair

AU - Karakiewicz, Pierre I

AU - Gontero, Paolo

AU - Chun, Felix K-H

AU - Fisch, Margit

AU - Scherr, Douglas S

AU - Shariat, Shahrokh F

PY - 2013

Y1 - 2013

N2 - PURPOSE: An increasing body of evidence suggests gender differences in the presentation and prognosis of bladder cancer. We aimed to assess the impact of gender on outcomes in patients with primary T1 high-grade (HG) urothelial carcinoma of the bladder (UCB).METHODS: We retrospectively analysed the data from 916 patients with primary T1HG UCB from 7 tertiary care centres. Patients were treated with transurethral resection of the bladder with or without intravesical instillation therapy (IVT). Univariable and multivariable Cox regression analyses assessed the effect of gender on outcomes.RESULTS: Within a median follow-up of 42.8 months, 365 (39.8 %) patients experienced disease recurrence, 104 (11.4 %) progression, 59 (6.4 %) cancer-specific mortality and 190 (20.7 %) mortality of any cause. Overall, 634 (69.2 %) patients received IVT of which 234 (25.5 %) received BCG therapy. Female gender (n = 190, 20.7 %) was associated with higher risk of disease recurrence (HR:1.359;1.071-1.724, p = 0.012) in all patients and in a subgroup of patients treated with BCG therapy (HR:1.717;1.101-2.677, p = 0.017). There was no difference between genders with regard to disease progression, cancer-specific mortality and any-cause mortality. In multivariable analyses that adjusted for the effects of concomitant carcinoma in situ (CIS), tumour size, number of tumours, and IVT, gender remained an independent predictor for disease recurrence (p = 0.026) when analysed in all patients, but not in the subgroup of BCG treated patients (p = 0.093).CONCLUSIONS: In patients with T1HG UCB, female gender is associated with higher risk of disease recurrence, but not with disease progression. This gender disparity may be due to differences in care and/or biology of UCB.

AB - PURPOSE: An increasing body of evidence suggests gender differences in the presentation and prognosis of bladder cancer. We aimed to assess the impact of gender on outcomes in patients with primary T1 high-grade (HG) urothelial carcinoma of the bladder (UCB).METHODS: We retrospectively analysed the data from 916 patients with primary T1HG UCB from 7 tertiary care centres. Patients were treated with transurethral resection of the bladder with or without intravesical instillation therapy (IVT). Univariable and multivariable Cox regression analyses assessed the effect of gender on outcomes.RESULTS: Within a median follow-up of 42.8 months, 365 (39.8 %) patients experienced disease recurrence, 104 (11.4 %) progression, 59 (6.4 %) cancer-specific mortality and 190 (20.7 %) mortality of any cause. Overall, 634 (69.2 %) patients received IVT of which 234 (25.5 %) received BCG therapy. Female gender (n = 190, 20.7 %) was associated with higher risk of disease recurrence (HR:1.359;1.071-1.724, p = 0.012) in all patients and in a subgroup of patients treated with BCG therapy (HR:1.717;1.101-2.677, p = 0.017). There was no difference between genders with regard to disease progression, cancer-specific mortality and any-cause mortality. In multivariable analyses that adjusted for the effects of concomitant carcinoma in situ (CIS), tumour size, number of tumours, and IVT, gender remained an independent predictor for disease recurrence (p = 0.026) when analysed in all patients, but not in the subgroup of BCG treated patients (p = 0.093).CONCLUSIONS: In patients with T1HG UCB, female gender is associated with higher risk of disease recurrence, but not with disease progression. This gender disparity may be due to differences in care and/or biology of UCB.

KW - Administration, Intravesical

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Carcinoma, Transitional Cell

KW - Combined Modality Therapy

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Regression Analysis

KW - Retrospective Studies

KW - Risk Factors

KW - Sex Factors

KW - Urinary Bladder Neoplasms

U2 - 10.1007/s00345-012-0996-9

DO - 10.1007/s00345-012-0996-9

M3 - SCORING: Journal article

C2 - 23196773

VL - 31

SP - 1029

EP - 1036

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 5

ER -